Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Graham J, Luthra R, Earnshaw S, Borker R. Cost-effectiveness of afatinib vs. erlotinib in the 1st-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion mutations. Poster presented at the 16th World Conference on Lung Cancer; September 6, 2015. Denver, CO.
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock SJ. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Curr Med Res Opin. 2015 Feb;31(2):289-97.
Ward MA, Fang G, Richards K, Walko C, Earnshaw SR, Happe LE, Blalock SJ. Comparative outcomes of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Poster presented at the 2014 AMCP Nexus; October 2014.
Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.
Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.
Kattan MW, Earnshaw SR, McDade CL, Black LK, Andriole GL. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial. Appl Health Econ Health Policy. 2011 Sep 1;9(5):305-15.
Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.
Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Bell CF, McDade CL, Black L, Earnshaw SR, Kattan MW. Considerations for modeling the cost-effectiveness of preventative prostate cancer treatments. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada.